Display options
Cite
Wang Y, Wang Z, Piha-Paul S, et al. Outcome analysis of Phase I trial patients with metastatic . Oncotarget. 2018;9(70):33258-33270doi: 10.18632/oncotarget.25947.
Wang, Y., Wang, Z., Piha-Paul, S., Janku, F., Subbiah, V., Shi, N., Hess, K., Broaddus, R., Shan, B., Naing, A., Hong, D., Tsimberidou, A. M., Karp, D., Lu, C., Papadimitrakopoulou, V., Heymach, J., Meric-Bernstam, F., & Fu, S. (2018). Outcome analysis of Phase I trial patients with metastatic . Oncotarget, 9(70), 33258-33270. https://doi.org/10.18632/oncotarget.25947
Wang, Yudong, et al. "Outcome analysis of Phase I trial patients with metastatic ." Oncotarget vol. 9,70 (2018): 33258-33270. doi: https://doi.org/10.18632/oncotarget.25947
Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, Heymach J, Meric-Bernstam F, Fu S. Outcome analysis of Phase I trial patients with metastatic . Oncotarget. 2018 Sep 07;9(70):33258-33270. doi: 10.18632/oncotarget.25947. eCollection 2018 Sep 07. PMID: 30279957; PMCID: PMC6161801.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Sep 07;9(70):33258-33270. doi: 10.18632/oncotarget.25947. eCollection 2018 Sep 07.

Outcome analysis of Phase I trial patients with metastatic .

Oncotarget

Yudong Wang, Zhijie Wang, Sarina Piha-Paul, Filip Janku, Vivek Subbiah, Naiyi Shi, Kenneth Hess, Russell Broaddus, Baoen Shan, Aung Naing, David Hong, Apostolia M Tsimberidou, Daniel Karp, Charles Lu, Vali Papadimitrakopoulou, John Heymach, Funda Meric-Bernstam, Siqing Fu

Affiliations

  1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  2. Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People's Republic of China.
  3. Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, People's Republic of China.
  4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  5. Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  6. Department of Cancer Research, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People's Republic of China.
  7. Department of Thoracic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 30279957 PMCID: PMC6161801 DOI: 10.18632/oncotarget.25947

[No abstract available.]

Keywords: KRAS; Phase I trial; TP53; non-small cell lung cancer; overall survival

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.

References

  1. Cancer Epidemiol Biomarkers Prev. 1999 Jul;8(7):625-34 - PubMed
  2. J Thorac Oncol. 2015 Mar;10(3):431-7 - PubMed
  3. Oncotarget. 2017 May 16;8(20):33796-33806 - PubMed
  4. J Clin Oncol. 2015 Sep 1;33(25):2753-62 - PubMed
  5. J Biomed Biotechnol. 2011;2011:583929 - PubMed
  6. Oncotarget. 2013 May;4(5):705-14 - PubMed
  7. N Engl J Med. 1987 Oct 8;317(15):929-35 - PubMed
  8. Cancer Res. 2015 Apr 1;75(7):1527-36 - PubMed
  9. Lung Cancer. 2014 Nov;86(2):121-5 - PubMed
  10. J Thorac Oncol. 2016 Jul;11(7):946-63 - PubMed
  11. Cell Death Differ. 2013 Jul;20(7):888-97 - PubMed
  12. Genes Dev. 2000 Jan 1;14(1):34-44 - PubMed
  13. Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10915-9 - PubMed
  14. J Mol Biol. 2004 Mar 5;336(5):1265-82 - PubMed
  15. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  16. J Clin Oncol. 2013 Mar 10;31(8):1112-21 - PubMed
  17. Oncotarget. 2016 Jun 7;7(23):35132-43 - PubMed
  18. Nat Commun. 2016 Sep 02;7:12685 - PubMed
  19. Nature. 2010 Nov 25;468(7323):567-71 - PubMed
  20. Cancer Res. 2015 Apr 1;75(7):1187-90 - PubMed
  21. J Thorac Oncol. 2015 May;10(5):768-777 - PubMed
  22. PLoS One. 2013 Nov 15;8(11):e80885 - PubMed
  23. Arch Pathol Lab Med. 2014 Nov;138(11):1449-58 - PubMed
  24. J Clin Oncol. 2013 Jun 10;31(17):2173-81 - PubMed
  25. World J Surg Oncol. 2015 Mar 28;13:128 - PubMed
  26. Nature. 2007 Aug 16;448(7155):807-10 - PubMed
  27. Cancer Inform. 2017 Feb 20;16:1176935117691267 - PubMed
  28. Mol Oncol. 2014 May;8(3):555-64 - PubMed
  29. Nature. 1964 Dec 12;204:1104-5 - PubMed
  30. J Clin Oncol. 1995 Aug;13(8):1893-903 - PubMed
  31. Int J Cancer. 2017 Apr 15;140(8):1860-1869 - PubMed
  32. Oncotarget. 2017 Apr 10;8(34):57680-57692 - PubMed
  33. Oncogene. 2007 May 14;26(22):3291-310 - PubMed
  34. Nat Rev Mol Cell Biol. 2008 Jul;9(7):517-31 - PubMed
  35. Mol Cancer Ther. 2011 Mar;10(3):385-94 - PubMed
  36. Cancer Res. 1994 Sep 15;54(18):4855-78 - PubMed
  37. J Clin Oncol. 2017 Jun 20;35(18):2018-2027 - PubMed
  38. J Clin Oncol. 1999 Feb;17(2):668-75 - PubMed
  39. J Clin Oncol. 2010 Nov 1;28(31):4769-77 - PubMed
  40. J Mol Biol. 1996 Mar 29;257(2):342-58 - PubMed
  41. Eur Respir J. 2012 Jul;40(1):177-84 - PubMed
  42. Mol Carcinog. 2015 Feb;54(2):93-101 - PubMed
  43. Cancer Res. 2012 May 15;72(10):2457-67 - PubMed
  44. Annu Rev Pharmacol Toxicol. 2016;56:23-40 - PubMed
  45. Clin Cancer Res. 2008 Sep 15;14(18):5731-4 - PubMed
  46. Cancer Res. 2004 Dec 15;64(24):8919-23 - PubMed
  47. Pathol Int. 2010 Oct;60(10):651-60 - PubMed
  48. Oncotarget. 2014 Nov 30;5(22):11168-79 - PubMed
  49. Nature. 2012 Sep 27;489(7417):519-25 - PubMed
  50. Ann Oncol. 2015 May;26(5):1012-8 - PubMed
  51. J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 - PubMed
  52. Oncologist. 2016 Dec;21(12):1450-1460 - PubMed
  53. Cancer Res. 1992 Sep 1;52(17):4799-804 - PubMed
  54. Mol Clin Oncol. 2016 Dec;5(6):705-713 - PubMed
  55. Cancer Cell. 2014 Mar 17;25(3):304-17 - PubMed
  56. Cancer Res. 2015 Apr 1;75(7):1205-15 - PubMed
  57. J Thorac Oncol. 2016 Jun;11(6):850-61 - PubMed

Publication Types